Literature DB >> 17570704

Reducing irinotecan-associated diarrhea in children.

Lars M Wagner1, Kristine R Crews, Clinton F Stewart, Carlos Rodriguez-Galindo, Rene Y McNall-Knapp, Karen Albritton, Alberto S Pappo, Wayne L Furman.   

Abstract

Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 17570704     DOI： 10.1002/pbc.21280

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  14 in total

1.  Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

Authors:  Steven G DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P Mosse; John M Maris; Denice Tsao-Wei; Araz Marachelian; Judith G Villablanca; Katherine K Matthay
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

2.  Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

Authors:  Steven G DuBois; Yael P Mosse; Elizabeth Fox; Rachel A Kudgus; Joel M Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M Maris; Clare J Twist; Kelly Goldsmith; M Meaghan Granger; Brian Weiss; Julie R Park; Margaret E Macy; Susan L Cohn; Greg Yanik; Lars M Wagner; Randall Hawkins; Jesse Courtier; Hollie Lai; Fariba Goodarzian; Hiroyuki Shimada; Najee Boucher; Scarlett Czarnecki; Chunqiao Luo; Denice Tsao-Wei; Katherine K Matthay; Araz Marachelian
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

3.  The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor.

Authors:  Kevin X Liu; Natalie B Collins; Katie A Greenzang; Elissa Furutani; Kevin Campbell; Andrew Groves; Elizabeth A Mullen; Suzanne Shusterman; Jennifer Spidle; Karen J Marcus; Brent R Weil; Christopher B Weldon; A Lindsay Frazier; Katherine A Janeway; Allison F O'Neill; Jennifer W Mack; Steven G DuBois; David S Shulman
Journal:  Pediatr Blood Cancer       Date:  2020-07-19       Impact factor: 3.167

4.  Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

Authors:  Lisa M McGregor; Clinton F Stewart; Kristine R Crews; Michael Tagen; Amy Wozniak; Jianrong Wu; M Beth McCarville; Fariba Navid; Victor M Santana; Peter J Houghton; Wayne L Furman; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2011-04-20       Impact factor: 3.167

5.  Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

Authors:  Lars M Wagner; Judith G Villablanca; Clinton F Stewart; Kristine R Crews; Susan Groshen; C Patrick Reynolds; Julie R Park; John M Maris; Randall A Hawkins; Heike E Daldrup-Link; Hollie A Jackson; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

Review 6.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

7.  Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Authors:  Steven G DuBois; Araz Marachelian; Elizabeth Fox; Rachel A Kudgus; Joel M Reid; Susan Groshen; Jemily Malvar; Rochelle Bagatell; Lars Wagner; John M Maris; Randall Hawkins; Jesse Courtier; Hollie Lai; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Denice Tsao-Wei; Katherine K Matthay; Yael P Mosse
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

8.  Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

Authors:  Lars M Wagner; John P Perentesis; Joel M Reid; Matthew M Ames; Stephanie L Safgren; Marvin D Nelson; Ashish M Ingle; Susan M Blaney; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

Review 9.  The microbiome in pediatric oncology.

Authors:  Seth J Rotz; Christopher E Dandoy
Journal:  Cancer       Date:  2020-06-13       Impact factor: 6.860

Review 10.  Prospects and challenges for the development of new therapies for Ewing sarcoma.

Authors:  Patrick J Grohar; Lee J Helman
Journal:  Pharmacol Ther       Date:  2012-10-18       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.